On tonight’s Mad Money on CNBC, Jim Cramer said he’s officially going "cautious" and noted that you can’t just start recommending stocks in the current market. He noted that we haven’t even seen a…
Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is $0.86 to $2.35.…
Bostwick Laboratories, Inc. submitted an IPO filing Friday, March 7. The filing shows a proposed maximum amount in securities as $100 million. The underwriters are listed as Banc of America, Wachovia Securities, William Blair,…
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) may have just joined the ranks of a biotech zombie, even if it doesn’t want to admit that. The company announced that top-line results from its SUN-MICRO Phase III…
Pfizer Inc. (NYSE: PFE) has given some of its basic data points for its analyst meeting today. For starters, the company has reaffirmed its guidance for 2008 that it previously offered. That guidance is…
Applera Corporation had an SEC Filing today saying its Board of Directors has authorized management to pursue a possible separation of the Celera Group (NYSE:CRA) from Applera. The completion of this proposal is subject…
CardioNet, Inc. has set the terms for its IPO in an amended SEC filing. The systems provider for monitoring real-time patient information intends to sell some 6.6 million shares in a price range of…
Two of the best-selling drugs in the US are Procrit from Johnson & Johnson (NYSE: JNJ) and Aranesp from Amgen (NASDAQ:AMGN). The products treat anemia in patients with kidney dialysis issues. Studies now show…
We do not cover every single index change, but we do cover the ones where it looks like it will impact individual stocks. Standard & Poor’s made an index change announcement this evening and…
A small biotech out of Australia called Prana Biotechnology Ltd. (NASDAQ: PRAN) today is trading up nearly 50% to a new 52-week high on favorable results in Alzheimer’s Disease studies. The company announced that…
Transoma Medical, Inc. withdrew its IPO filing this morning, citing “unfavorable market conditions.” The company originally filed its IPO paperwork on October 12, 2007 and had planned to trade on the Nasdaq Global Market…
Adherex Technologies Inc. (AMEX: ADH) has announced that it has received an orphan drug designation for its ADH-1 from the FDA for the use of ADH-1 in conjunction with melphalan for the treatment of…
Teva Pharmaceutical (NASDAQ: TEVA – News) has some pretty loft goals for itself at its Investor Day presentation. If you trust the company’s history and its pipeline of candidates under trials and under pending…
Antigenics Inc. (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week range is $1.54…
The uproar about Heparin, a widely-used drug marketed by Baxter International (NYSE: BAX), is just beginning. As The Wall Street Journal writes "Baxter said the active ingredient for its heparin was supplied by Scientific…